Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C
Brief Summary: A Phase 3 study to evaluate the efficacy and safety of two dosing regimens of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV).


Options:
A: Arm Label: PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week; Type: PLACEBO_COMPARATOR; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Ribavirin, Other: Placebo | Arm Label: Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week; Type: EXPERIMENTAL; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Telaprevir, Drug: Ribavirin, Other: Placebo | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week; Type: EXPERIMENTAL; Interventions: Biological: Pegylated Interferon Alfa 2a, Drug: Telaprevir, Drug: Ribavirin | Intervention Type: BIOLOGICAL; Name: Pegylated Interferon Alfa 2a; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week
B: Arm Label: Group A: T12/PR48; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin, Drug: Placebo | Arm Label: Group B: T12(DS)/PR48; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Peg-IFN-alfa-2a, Drug: Ribavirin, Drug: Placebo | Arm Label: Group C: Pbo/PR48; Type: EXPERIMENTAL; Interventions: Drug: Peg-IFN-alfa-2a, Drug: Ribavirin, Drug: Placebo | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48 | Intervention Type: DRUG; Name: Peg-IFN-alfa-2a; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48, Group C: Pbo/PR48 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48, Group C: Pbo/PR48 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group A: T12/PR48, Group B: T12(DS)/PR48, Group C: Pbo/PR48
C: Arm Label: 1. Placebo + PEG + RBV; Type: PLACEBO_COMPARATOR; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Placebo | Arm Label: 2. Boceprevir + PEG + RBV - 24 Weeks (RGT); Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Arm Label: 3. Boceprevir + PEG + RBV - 44 Weeks; Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Intervention Type: BIOLOGICAL; Name: Peginterferon alfa-2b (PEG); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1. Placebo + PEG + RBV | Intervention Type: DRUG; Name: Boceprevir; Assigned to Arm(s): 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks
D: Arm Label: Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg); Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325 | Arm Label: Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV; Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: BMS-790052, Drug: BMS-791325, Drug: Ribavirin | Intervention Type: DRUG; Name: BMS-650032; Assigned to Arm(s): Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV | Intervention Type: DRUG; Name: BMS-790052; Assigned to Arm(s): Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV | Intervention Type: DRUG; Name: BMS-791325; Assigned to Arm(s): Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg), Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg), Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg), Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg), Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV

Answer: A